8-K: Aethlon Medical Updates Outstanding Shares Post-Offering

Aethlon Medical, Inc. announced 7,373,156 outstanding shares as of September 12, 2025, following a recent best-efforts public offering.

Summary

• Aethlon Medical, Inc. reported its total outstanding shares as of the close of business on September 12, 2025.
• The company has 7,373,156 outstanding shares.
• This share count reflects the impact of a recently completed financing through a best-efforts public offering.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual update regarding outstanding shares post-financing, providing no performance or forward-looking information to sway sentiment.

Positives

• The successful completion of a recent financing through a best-efforts public offering indicates the company's ability to raise capital.

Negatives

• The increase in outstanding shares to 7,373,156 suggests dilution for existing shareholders due to the recent public offering.

Industry Context

For medical device and biotechnology companies like Aethlon Medical, public offerings are a common mechanism to secure capital for research and development, clinical trials, or general corporate purposes. This update on outstanding shares is a standard disclosure following such a financing event, providing transparency on the company's capital structure.

Stakeholder Impact

• Shareholders: Existing shareholders experienced dilution due to the increase in outstanding shares from the public offering.
• Company: The company likely received capital from the offering, which can be used to fund operations, research, and development.

Key Dates

Keywords

Aethlon Medical, AEMD, outstanding shares, public offering, financing, SEC filing, 8-K, biotechnology, medical devices